Open Access. Powered by Scholars. Published by Universities.®
- Keyword
-
- Cell Line (2)
- Cell Line, Tumor (2)
- Humans (2)
- Tumor (2)
- Anthocyanins (1)
-
- Antineoplastic Agents (1)
- BT474 Cell (1)
- Breast Cancer Cell (1)
- Breast Neoplasms (1)
- Cation (1)
- Cell Adhesion (1)
- Cell Movement (1)
- Cells (1)
- Cost effectiveness (1)
- ErbB-2 (1)
- Ethanol (1)
- Ethanol Exposure (1)
- Fluorescence (1)
- Focal Adhesion (1)
- Gene Expression Profiling (1)
- Gene Expression Regulation (1)
- Gene Expression Regulation, Neoplastic (1)
- Glucosides (1)
- Hematopoietic (1)
- Immunoblotting (1)
- Immunoprecipitation (1)
- Intercellular Signaling Peptides and Proteins (1)
- Leukemias (1)
- Lymphoma (1)
- Male (1)
Articles 1 - 4 of 4
Full-Text Articles in Medicine and Health Sciences
Dysregulation Of The Mitogen Granulin In Human Cancer Through The Mir-15/107 Microrna Gene Group, Wang-Xia Wang, Natasha Kyprianou, Xiaowei Wang, Peter T. Nelson
Dysregulation Of The Mitogen Granulin In Human Cancer Through The Mir-15/107 Microrna Gene Group, Wang-Xia Wang, Natasha Kyprianou, Xiaowei Wang, Peter T. Nelson
Pathology and Laboratory Medicine Faculty Publications
Granulin (GRN) is a potent mitogen and growth factor implicated in many human cancers, but its regulation is poorly understood. Recent findings indicate that GRN is regulated strongly by the microRNA miR-107, which functionally overlaps with miR-15, miR-16, and miR-195 due to a common 5′ sequence critical for target specificity. In this study, we queried whether miR-107 and paralogs regulated GRN in human cancers. In cultured cells, anti-argonaute RNA coimmunoprecipitation with downstream microarray analyses indicates that GRN mRNA is directly targeted by numerous miR-15/107 miRNAs. We further tested this association in human tumors. MiR-15 and miR-16 are known to be …
Cyanidin-3-Glucoside Inhibits Ethanol-Induced Invasion Of Breast Cancer Cells Overexpressing Erbb2, Mei Xu, Kimberly A. Bower, Siying Wang, Jacqueline A. Frank, Gang Chen, Min Ding, Shiow Wang, Xianglin Shi, Zunji Ke, Jia Luo
Cyanidin-3-Glucoside Inhibits Ethanol-Induced Invasion Of Breast Cancer Cells Overexpressing Erbb2, Mei Xu, Kimberly A. Bower, Siying Wang, Jacqueline A. Frank, Gang Chen, Min Ding, Shiow Wang, Xianglin Shi, Zunji Ke, Jia Luo
Internal Medicine Faculty Publications
BACKGROUND: Ethanol is a tumor promoter. Both epidemiological and experimental studies suggest that ethanol may enhance the metastasis of breast cancer cells. We have previously demonstrated that ethanol increased the migration/invasion of breast cancer cells expressing high levels of ErbB2. Amplification of ErbB2 is found in 20-30% of breast cancer patients and is associated with poor prognosis. We sought to identify agents that can prevent or ameliorate ethanol-induced invasion of breast cancer cells. Cyanidin-3-glucoside (C3G), an anthocyanin present in many vegetables and fruits, is a potent natural antioxidant. Ethanol exposure causes the accumulation of intracellular reactive oxygen species (ROS). This …
Organic Cation Transporter Preferentially Expressed In Hematopoietic Cells And Leukemias And Uses Thereof, Jeffrey A. Moscow, Xin Lu, Craig Jordan
Organic Cation Transporter Preferentially Expressed In Hematopoietic Cells And Leukemias And Uses Thereof, Jeffrey A. Moscow, Xin Lu, Craig Jordan
Markey Cancer Center Faculty Patents
A novel organic cation transporter (OCT) gene, OCT 6, and use thereof is described. The OCT6 gene is preferentially expressed in human hematopoietic tissues, including CD34+ cells and leukemia cells. Its narrow tissue distribution, substrate specificity, and close homology to other cell membrane transporters make OCT6 an attractive target for the treatment of myeloid diseases.
Rituximab In The Treatment Of B-Cell Non-Hodgkin Lymphoma, Focus On Outcomes And Comparative Effectiveness, Firas Badin, John Hayslip
Rituximab In The Treatment Of B-Cell Non-Hodgkin Lymphoma, Focus On Outcomes And Comparative Effectiveness, Firas Badin, John Hayslip
Markey Cancer Center Faculty Publications
Rituximab is an important and well established component in the treatment of many patients with B-cell non-Hodgkin lymphoma. In this paper we review recent clinical trials investigating the addition of rituximab to standard chemotherapy regimens for treatment of patients with diffuse large B cell lymphoma and follicular lymphoma. This report focuses upon treatment efficacy, quality of life, and safety of rituximab or rituximab-containing regimens. More uniquely, we review economic aspects of lymphoma treatments, including the cost of standard chemotherapy regimens with or without rituximab, cost effectiveness of rituximab in both induction and maintenance treatment, and lymphoma's impacts on patient's productivity …